Indian Court Dismisses Teva’s Plea To Halt Natco’s Generic Copaxone Exports
This article was originally published in PharmAsia News
Executive Summary
A two-year patent infringement case reached a conclusion with the Delhi High Court favoring Natco in a dispute over generic versions of Teva’s top-selling MS drug. If the court had sided with Teva, launch plans for the United States may have been delayed for Natco’s partner Mylan.